Gwendolyn Wu is a reporter at BioPharma Dive. She specializes in covering biotech startups, venture capital, and the healthcare ecosystem, with a keen focus on the intersection of medicine and business. Gwendolyn's work has been featured in notable publications including the Houston Chronicle, San Francisco Chronicle, and Yahoo Finance.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Not enough data
Gwendolyn Wu's coverage primarily revolves around the biotechnology industry, particularly focusing on press releases and private sector announcements. She is likely to be interested in pitches related to groundbreaking developments in biotech, such as new drug approvals, IPO filings, or significant funding rounds.
Given her focus on business (16%) within the context of biotechnology (45%), she may also be receptive to news about mergers and acquisitions involving biotech companies or innovative business strategies within the industry.
As Gwendolyn does not have a specific geographic focus mentioned, it is likely that she covers global developments in the field of biotechnology. Therefore, international perspectives and stories with broad relevance are more likely to resonate with her reporting interests.
This information evolves through artificial intelligence and human feedback. Improve this profile .
The startup claims its proprietary linker molecules can yield ADCs that are more precise and potent than existing options.
By: Gwendolyn Wu
Archon Biosciences, co-founded by the winner of the 2024 Nobel Prize in Chemistry, emerged from stealth Wednesday with $20 million in seed capital.
The biotech expects three Phase 2 readouts in urticaria and eczema over the next two years, and will keep its âoptions openâ regarding a future IPO, its CEO said.
Pioneers like Alnylam Pharmaceuticals have led the RNA interference field for years. Now, a crop of young biotechs is building on that foundation by taking the drugmaking technology in new directions.
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for Parkinsonâs and another neurodegenerative condition.
The deal with Vesalius Therapeutics is the latest pharma validation for Flagship, which has in recent years allied with Pfizer and Novo Nordisk.
The California biotech has drawn partnerships with Eli Lilly and J&J on the promise of its approach to rebalancing the immune system.
This story was originally published on BioPharma Dive . To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter
The startup, Pep2Tango, is combining four methods of accelerating weight loss into one medicine in the hopes of developing a treatment that can improve upon drugs like Wegovy and Zepbound.
By: Julia Himmel, Gwendolyn Wu, Ben Fidler
Venture capital firms incubate, grow and finance dozens of new drug companies each year. Follow the money they channel into the industry with this database.
(833) 317-6278 
